Tiger Brokers

BUZZ-BioAge Labs tumbles on scrapping mid-stage trial of experimental obesity drug

Reuters
Dec 07, 2024

** Shares of drug developer BioAge Labs crater 67.6% to $6.52 in extended trading

** Co discontinues mid-stage trial of its experimental obesity drug after high levels of certain liver enzymes observed in some patients

** BioAge's experimental drug, azelaprag, mimics activity of the exerkine apelin, a peptide released in response to exercise due to muscle contraction

** Co was studying azelaprag as a monotherapy and in combination with Eli Lilly's tirzepatide

** BioAge has stopped dosing all patients and plans to further analyze data from people who have been enrolled

** As of last close, stock down ~10% since its market debut in September

(Reporting by Juveria Tabassum in Bengaluru)

((Juveria.Tabassum@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10